Evaluation of muc1, muc2, muc5ac, and muc6 expression differences in lung adenocarcinoma subtypes by using a final immunoreactivity score (firs)
Turkish Journal of Pathology · 2022
DOI: 10.5146/tjpath.2022.01593 ↗Kurz gefasst
Fachartikel in der Zeitschrift Turkish Journal of Pathology, 2022. Verfasst von Melek Buyuk und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Istanbul Faculty of Medicine, Istanbul University, ISTANBUL, TURKEY. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Adenocarcinoma, Mucinous, Lung Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Istanbul Faculty of Medicine, Istanbul University, ISTANBUL, TURKEY.
Zitieren
APA
Buyuk, M., Ozluk, Y., Bakkaloglu, D. V., Ozkan, B., Firat, P., & Yilmazbayhan, D. (2022). Evaluation of muc1, muc2, muc5ac, and muc6 expression differences in lung adenocarcinoma subtypes by using a final immunoreactivity score (firs). Turkish Journal of Pathology. https://doi.org/10.5146/tjpath.2022.01593
Vancouver
Buyuk M, Ozluk Y, Bakkaloglu DV, Ozkan B, Firat P, Yilmazbayhan D. Evaluation of muc1, muc2, muc5ac, and muc6 expression differences in lung adenocarcinoma subtypes by using a final immunoreactivity score (firs). Turkish Journal of Pathology. 2022. doi:10.5146/tjpath.2022.01593
BibTeX
@article{Buyuk2022,
author = {Buyuk, Melek and Ozluk, Yasemin and Bakkaloglu, Dogu Vuralli and Ozkan, Berker and Firat, Pinar and Yilmazbayhan, Dilek},
title = {Evaluation of muc1, muc2, muc5ac, and muc6 expression differences in lung adenocarcinoma subtypes by using a final immunoreactivity score (firs)},
journal = {Turkish Journal of Pathology},
year = {2022},
doi = {10.5146/tjpath.2022.01593}
}
EUVIMED